We are live on ! Find out more
CSTL icon

Castle Biosciences

89 hedge funds and large institutions have $220M invested in Castle Biosciences in 2020 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

164% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 14

33% more funds holding

Funds holding: 6789 (+22)

25% more capital invested

Capital invested by funds: $176M → $220M (+$44.5M)

13.02% more ownership

Funds ownership: 29.93%42.94% (+13%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
89
Holders Change
+22
Holders Change %
+32.84%
% of All Funds
1.96%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
32
Increased
37
Reduced
14
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
FAM
51
Fred Alger Management
New York
$477K -$181K -6,000 -27%
MPAM
52
Monarch Partners Asset Management
Massachusetts
$459K +$158K +5,230 +51%
Marshall Wace
53
Marshall Wace
United Kingdom
$448K +$454K +15,031 New
GPGA
54
Grandeur Peak Global Advisors
Utah
$446K -$520K -17,250 -54%
State of Wisconsin Investment Board
55
State of Wisconsin Investment Board
Wisconsin
$435K +$441K +14,600 New
California State Teachers Retirement System (CalSTRS)
56
California State Teachers Retirement System (CalSTRS)
California
$429K +$265K +8,794 +157%
Two Sigma Advisers
57
Two Sigma Advisers
New York
$402K -$27.2K -900 -6%
PAM
58
Panagora Asset Management
Massachusetts
$398K +$397K +13,166 +6,616%
JP Morgan Chase
59
JP Morgan Chase
New York
$374K +$328K +10,855 +643%
DTL
60
Dynamic Technology Lab
Singapore
$337K +$341K +11,312 New
CC
61
Claybrook Capital
Massachusetts
$299K +$303K +10,026 New
HIM
62
Hillsdale Investment Management
Ontario, Canada
$281K +$284K +9,400 New
Prudential Financial
63
Prudential Financial
New Jersey
$280K +$284K +9,396 New
RhumbLine Advisers
64
RhumbLine Advisers
Massachusetts
$276K +$279K +9,244 New
CMBA
65
C.M. Bidwell & Associates
Hawaii
$263K +$202K +6,685 +311%
Acadian Asset Management
66
Acadian Asset Management
Massachusetts
$255K +$258K +8,565 New
MWNA
67
Marshall Wace North America
New York
$227K +$229K +7,598 New
UBS Group
68
UBS Group
Switzerland
$199K +$45K +1,490 +29%
AIG
69
American International Group
New York
$167K +$97.7K +3,238 +137%
New York State Common Retirement Fund
70
New York State Common Retirement Fund
New York
$164K
MIM
71
MetLife Investment Management
New Jersey
$137K +$139K +4,608 New
Ensign Peak Advisors
72
Ensign Peak Advisors
Utah
$120K -$493K -16,339 -80%
Citigroup
73
Citigroup
New York
$113K +$51.5K +1,707 +82%
SG Americas Securities
74
SG Americas Securities
New York
$112K +$114K +3,767 New
Deutsche Bank
75
Deutsche Bank
Germany
$99K +$60.9K +2,019 +154%

CSTL Hedge Fund Activity: Q1 2020 in Review

89 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q1 2020, worth a combined $220M — up 25% from $176M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new CSTL positions and 10 closed out — a net gain of 22 holders — while 37 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $8.45M. The largest seller was Portolan Capital Management, cutting an estimated $5.13M.

  • 89 institutional investors held Castle Biosciences (CSTL) as of Q1 2020, up from 67 in Q4 2019.
  • Funds reported $220M of Castle Biosciences stock for Q1 2020, up 25% quarter-over-quarter.
  • 32 funds opened new Castle Biosciences positions in Q1 2020 and 10 closed out, a net change of +22 holders.
  • The largest Castle Biosciences buyer in Q1 2020 was BlackRock, an estimated $8.45M added.
  • The largest Castle Biosciences seller in Q1 2020 was Portolan Capital Management, an estimated $5.13M sold.

Based on aggregated 13F filings for Q1 2020.